共 24 条
- [11] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) : 2380 - 2388Maemondo, MakotoInoue, AkiraKobayashi, KunihikoSugawara, ShunichiOizumi, SatoshiIsobe, HiroshiGemma, AkihikoHarada, MasaoYoshizawa, HirohisaKinoshita, IchiroFujita, YukaOkinaga, ShojiHirano, HarutoYoshimori, KozoHarada, ToshiyukiOgura, TakashiAndo, MasahiroMiyazawa, HitoshiTanaka, TomoakiSaijo, YasuoHagiwara, KoichiMorita, SatoshiNukiwa, Toshihiro
- [12] Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) : 2513 - 2520Mitsudomi, TKosaka, TEndoh, HHorio, YHida, TMori, SHatooka, SShinoda, MTakahashi, TYatabe, Y
- [13] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) : 629 - 640Mok, T. S.Wu, Y. -L.Ahn, M. -J.Garassino, M. C.Kim, H. R.Ramalingam, S. S.Shepherd, F. A.He, Y.Akamatsu, H.Theelen, W. S. M. E.Lee, C. K.Sebastian, M.Templeton, A.Mann, H.Marotti, M.Ghiorghiu, S.Papadimitrakopoulou, V. A.
- [14] Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. LANCET RESPIRATORY MEDICINE, 2019, 7 (05) : 387 - 401Reck, MartinMok, Tony S. K.Nishio, MakotoJotte, Robert M.Cappuzzo, FedericoOrlandi, FranciscoStroyakovskiy, DaniilNogami, NaoyukiRodriguez-Abreu, DelvysMoro-Sibilot, DenisThomas, Christian A.Barlesi, FabriceFinley, GeneLee, AnthonyColeman, ShelleyDeng, YuKowanetz, MarcinShankar, GeethaLin, WeiSocinski, Mark A.
- [15] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. LANCET ONCOLOGY, 2012, 13 (03) : 239 - 246Rosell, RafaelCarcereny, EnricGervais, RadjVergnenegre, AlainMassuti, BartomeuFelip, EnriquetaPalmero, RamonGarcia-Gomez, RamonPallares, CintaMiguel Sanchez, JosePorta, RutCobo, ManuelGarrido, PilarLongo, FlaviaMoran, TeresaInsa, AmeliaDe Marinis, FilippoCorre, RomainBover, IsabelIlliano, AlfonsoDansin, Ericde Castro, JavierMilella, MicheleReguart, NoemiAltavilla, GiuseppeJimenez, UlpianoProvencio, MarianoAngel Moreno, MiguelTerrasa, JosefaMunoz-Langa, JoseValdivia, JavierIsla, DoloresDomine, ManuelMolinier, OlivierMazieres, JulienBaize, NathalieGarcia-Campelo, RosarioRobinet, GillesRodriguez-Abreu, DelvysLopez-Vivanco, GuillermoGebbia, VittorioFerrera-Delgado, LiobaBombaron, PierreBernabe, ReyesBearz, AlessandraArtal, AngelCortesi, EnricoRolfo, ChristianSanchez-Ronco, MariaDrozdowskyj, Ana
- [16] Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. LANCET ONCOLOGY, 2019, 20 (05) : 625 - 635Saito, HaruhiroFukuhara, TatsuroFuruya, NaokiWatanabe, KanaSugawara, ShunichiIwasawa, ShunichiroTsunezuka, YoshioYamaguchi, OuOkada, MorihitoYoshimori, KozoNakachi, IchiroGemma, AkihikoAzuma, KoichiKurimoto, FutoshiTsubata, YukariFujita, YukaNagashima, HiromiAsai, GyoWatanabe, SatoshiMiyazaki, MasakiHagiwara, KoichiNukiwa, ToshihiroMorita, SatoshiKobayashi, KunihikoMaemondo, Makoto
- [17] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) : 2542 - 2550Sandler, AlanGray, RobertPerry, Michael C.Brahmer, JulieSchiller, Joan H.Dowlati, AfshinLilenbaum, RogerioJohnson, David H.
- [18] Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study[J]. LANCET ONCOLOGY, 2014, 15 (11) : 1236 - 1244Seto, TakashiKato, TerufumiNishio, MakotoGoto, KoichiAtagi, ShinjiHosomi, YukioYamamoto, NoboruHida, ToyoakiMaemondo, MakotoNakagawa, KazuhikoNagase, SeisukeOkamoto, IsamuYamanaka, TakeharuTajima, KoseiHarada, RyosukeFukuoka, MasahiroYamamoto, Nobuyuki
- [19] Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (01) : 1 - 11Sheng, MiaomiaoWang, FangZhao, YueguangLi, ShanshanWang, XiaojieShou, TaoLuo, YingTang, Wenru
- [20] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02) : 113 - 125Soria, J. -C.Ohe, Y.Vansteenkiste, J.Reungwetwattana, T.Chewaskulyong, B.Lee, K. H.Dechaphunkul, A.Imamura, F.Nogami, N.Kurata, T.Okamoto, I.Zhou, C.Cho, B. C.Cheng, Y.Cho, E. K.Voon, P. J.Planchard, D.Su, W. -C.Gray, J. E.Lee, S. -M.Hodge, R.Marotti, M.Rukazenkov, Y.Ramalingam, S. S.Boyer, MichaelLee, CheeHughes, BrettO'Byrne, KennethBriggs, PeterMilward, MichaelJohn, ThomasDemedts, IngelVansteenkiste, JohanBustin, FrederiqueBarrios, Carlos HenriqueTimcheva, ConstantaButts, CharlesGoss, GlenwoodJuergens, RosalynLeighl, NatashaCheng, SusannaBurkes, RonaldZhou, CaicunZhang, HelongShu, YongqianCheng, YingZhou, QingLi, WeiFeng, GuoshengHe, Yong